These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28094040)

  • 1. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
    Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
    Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
    Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
    Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
    Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
    Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
    J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
    Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
    McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
    Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
    Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
    Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
    Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
    Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Burger RA; Deng W; Makker V; Collins Y; Gray H; Debernardo R; Martin LP; Aghajanian C
    Gynecol Oncol; 2018 Sep; 150(3):466-470. PubMed ID: 30041929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
    Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
    Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
    Necchi A; Lo Vullo S; Mariani L; Raggi D; Giannatempo P; Calareso G; Togliardi E; Crippa F; Di Genova N; Perrone F; Colecchia M; Paolini B; Pelosi G; Nicolai N; Procopio G; Salvioni R; De Braud FG
    Invest New Drugs; 2016 Apr; 34(2):236-42. PubMed ID: 26873642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
    [No Abstract]   [Full Text] [Related]  

  • 18. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962).
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27007010
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
    Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
    Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.